The 20-Day Lot Study Isn’t A CLIA Requirement

It’s a practice borrowed from CLSI C24 — written for unassayed quantitative controls in clinical chemistry. For assayed, qualitative molecular controls, the regulation asks for something narrower. This guidance shows you exactly where the line is. 

Built on CLIA, CLSI EP23/EP26/EP12, and CMS IQCP standards. Prepared by Streck. 

What’s inside

• Where 42 CFR 493.1256(d)(3), (d)(4), and (d)(10) draw the line between control lot transitions and new assay implementation — and why conflating them leads to over- or under-verification 

• Why the 20-day tradition comes from CLSI C24 (built for unassayed quantitative controls) and doesn’t govern assayed or qualitative molecular controls 

• The 1+4 Model: a phased, documented framework (1 confirmatory run + 4 monitoring runs) built for labs running an active IQCP 

• The four conditions under which a single confirmatory run satisfies the regulatory minimum — and when it doesn’t 

• A decision framework matched to your control type, IQCP status, and risk tolerance 

Who this is for: 
Laboratory quality stewards, laboratory directors, and lab technicians in molecular diagnostics and infectious disease testing — particularly labs operating under an IQCP that want to right-size verification without inviting an accreditation finding.